Results of Annual General Meeting
13/02/2023 17:50
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230213:nRSM7829Pa&default-theme=true
RNS Number : 7829P Cellular Goods PLC 13 February 2023
Press release
13 February 2023
Cellular Goods PLC
('Cellular Goods' or 'the Company')
Results of Annual General Meeting
Cellular Goods (LSE: CBX), a UK-based wellness company providing premium
consumer products formulated with lab-produced cannabinoids, is pleased to
announce that all resolutions proposed at the Annual General Meeting held
earlier today were duly passed on a show of hands.
For further information please contact:
Cellular Goods
Darcy Taylor via Tancredi +44 207 887 7633
Chairman and interim CEO
Neil Thapar +44 787 645 5323
Investor Relations
Tennyson Securities
Corporate Broker & Adviser
Peter Krens +44 207 186 9030
Alan Howard
Novum Securities
Corporate Broker
Colin Rowbury
Jon Belliss +44 207 399 9427
Tancredi Intelligent Communication
Media Relations
Helen Humphrey +44 744 922 6720
Charlie Hobbs +44 789 755 7112
cellulargoods@tancredigroup.com (mailto:cellulargoods@tancredigroup.com)
About Cellular Goods PLC:
Cellular Goods is a UK-based wellness company that provides premium products
based on lab-made cannabinoids. It was established in August 2018 to develop
efficacy-led and research-backed cannabinoid-powered wellness products. The
initial focus is on three product verticals: Feel Better, Look Better and
Function Better. These three verticals encompass Cellular Goods' premium CBG
skincare and CBD wellness with the first products launched in December 2021.
The Company's shares are listed on the main market of the London Stock
Exchange. www.cellular-goods.com (http://www.cellular-goods.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGUOSBROWUUAAR